Pregnancy test

Phase 2Biologic

AAssistance Publique - Hôpitaux de Paris

Pregnancy test is one of 35 biologic programs targeting Juvenile Dermatomyositis. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Juvenile DermatomyositisActive, not recruiting

Lung CancerActive, not recruiting

Juvenile DermatomyositisPhase 2

Active, not recruiting

Lung CancerPhase 2

Active, not recruiting

Competition

Competitive Landscape

686 competitors in Lung Cancer

#DrugCompanyPhaseTrials

Tecentriq

Roche

Preclinical

9 2

Libtayo

Regeneron

Preclinical

3 3

Vizimpro

Pfizer

Preclinical

3 4

Folvite

Xylocaine

2 6

Immunotherapy

Bristol-Myers Squibb

Preclinical

5 7

Pregnancy test

AAssistance Publique - Hôpitaux de Paris

Phase 2

1 8

Paclitaxel and Carboplatin

Bristol-Myers Squibb

Preclinical

2 9

Rilotumumab

Amgen

Preclinical

2 10

Precedex

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

N/ARecruiting

Systemic

NCT05042830

Q4 2030

Phase 2Recruiting

Lung Cancer

NCT06620835

Clinical

Trials by Indication[1]

Haemochromatosis1 trial

Estimation of Myocardial Iron Overload by 3 Tesla MRI in HFE Hereditary Haemochromatosis

Completed·RRennes University Hospital·N/A·NCT02099214·66 enrolled

Lung Cancer1 trial

Trial for Local Ablative Treatment (LAT) Optimization in Patients With Advanced Non-Small Cells Lung Cancer (NSCLC) Presenting an Anaplastic Lymphoma Kinase (ALK) Rearrangement Treated by Brigatinib

Recruiting·GGroupe Francais De Pneumo-Cancerologie·Phase 2·NCT06620835·45 enrolled

Systemic1 trial

Contribution of Nasal IgE Production to the Boost of Systemic Allergen-specific IgE Upon Nasal Allergen Contact

Recruiting·MMedical University of Vienna·N/A·NCT05042830·30 enrolled

Juvenile Dermatomyositis1 trial

Baricitinib in the Treatment of New-onset Juvenile Dermatomyositis (MYOCIT)

Completed·AAssistance Publique - Hôpitaux de Paris·Phase 2·NCT05524311·16 enrolled

CAR1 trial

Determination of Carcinogens Nicotine in Electronic Cigarettes Users

Unknown status·AAssistance Publique - Hôpitaux de Paris·N/A·NCT02897401·80 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for Pregnancy test. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Pregnancy test compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Pregnancy test. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Assistance Publique - Hôpitaux de Paris company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 2[1]
Company: AAssistance Publique - Hôpitaux de Paris

Pregnancy test

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2026

Q4 2030

Trials by Indication[1]

Haemochromatosis1 trial

Lung Cancer1 trial

Systemic1 trial

Juvenile Dermatomyositis1 trial

CAR1 trial

References

Drug Info

Quick Facts

Related News